Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma

✍ Scribed by M. Arland; S. Leuner; S. Lange; R. Bartsch; C. Kahl; A. Florschütz; A. Franke; H.-G. Höffkes

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 67 KB
• Volume: 19
• Category: Article
• ISSN: 0278-0232
• DOI: 10.1002/hon.669

✦ Synopsis

Abstract

In general, the mobilization of peripheral blood progenitor cells (PBPC) in multiple myeloma (MM) patients is poor and is achieved in most cases by combined cyclophosphamide and G‐CSF. This study was performed to examine the efficacy of combined ifosfamide/epirubicine and G‐CSF for PBPC mobilization and purging. Sixteen patients suffering from multiple myeloma in stage II/A and III/A according to Durie and Salmon underwent chemotherapy consisting of a total of three cycles of ifosfamide (3 g/m^2^ on days 1 and 2 and epirubicine 80 mg/m^2^ on day 1) and G‐CSF (10 or 20 µg/kg body weight (BW) daily until harvesting). PBPC harvesting was performed after the first and third cycle of chemotherapy. The median number of PBPC after the first cycle of chemotherapy was 7.79×10^6^ CD34+ cells/kg BW (ranging from 0.94–26.36×10^6^) and 6.38×10^6^ CD34+ cells/kg BW (ranging from 0.79–29.31×10^6^) after the third cycle of chemotherapy. Clinical re‐evaluation after three cycles of chemotherapy showed 13 (81 per cent) patients in partial remission (PR), two (12 per cent) in complete remission (CR) and one (6.25 per cent) in stable disease (SD). No major side‐effects were observed, six patients developed hematological toxicity stage IV WHO for a median of 3.9 days but no serious infection episodes occurred. Combined ifosfamide/epirubicin and standard G‐CSF is able to mobilize sufficient PBPC without serious side‐effects for patients with MM and for purging procedures resulting in a high proportion of complete remissions after tandem high‐dose melphalan chemotherapy. Copyright © 2001 John Wiley & Sons, Ltd.